

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944

Status	RECRUITING
Phase	Phase 3
Sponsor	Zealand Pharma
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (6)

- Signed informed consent;
 - Age of 18 to 90 years;
 - A diagnosis of SBS, defined as having a small bowel with an estimated length of less than 200 cm (equal to 79 inches) in continuity (latest intestinal resection e6 months before screening);
 - Stable PS need of e3 days per week;
 - No restorative surgery planned during the trial period;
- ... and 1 more (see full listing online)

Exclusion (4)

- More than 2 SBS- or PS-related hospitalizations within 6 months before screening;
- Poorly controlled Inflammatory Bowel Disease (IBD) that is moderately or severely active or a fistula that can interfere with the measurements or examinations required in the trial;
- History of colorectal cancer or any other type of cancer (except for margin-free resected cutaneous basal, squamous cell carcinoma or adequately treated in situ cervical cancer) unless the patient has been disease-free for at least 5 years; ongoing bowel obstruction;
- BMI ≤ 18.5 kg/m².

Locations (19 total)

Washington University Center for Advanced Medicine, St Louis, Missouri, United States
New York Presbyterian Hospital-Columbia University Medical Center, New York, New York, United States
Universitätsklinikum AKH Wien, Vienna, Vienna, Austria
... and 16 more locations